Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.47 |
| ▸ | FNTB | P49356 | 2/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422071 | 1.00 | POLB (0.52) | POLBPSMB8PSMB5FNTAFNTB | |
| Methionine SCHEMBL7404727 | 0.92 | FNTA (0.51) | POLBPSMB8PSMB5FNTAFNTB | |
| SCHEMBL2330760 | 0.88 | PPID (0.55) | POLBFNTAFNTBPGGT1BANPEP | |
| SCHEMBL2330757 | 0.88 | PPID (0.55) | POLBFNTAFNTBPGGT1BANPEP | |
| SCHEMBL2328031 | 0.87 | L3MBTL1 (0.56) | POLBFNTAFNTBPGGT1BTSHR | |
| SCHEMBL2328029 | 0.87 | L3MBTL1 (0.56) | POLBFNTAFNTBPGGT1BTSHR | |
| SCHEMBL2334144 | 0.85 | POLB (0.52) | POLBFNTAFNTBPGGT1BANPEP | |
| SCHEMBL2334148 | 0.85 | POLB (0.52) | POLBFNTAFNTBPGGT1BANPEP | |
| SCHEMBL6136442 | 0.84 | ALDH1A1 (0.48) | POLBFNTAFNTBPGGT1BALDH1A1 | |
| SCHEMBL4419164 | 0.84 | ALDH1A1 (0.48) | POLBFNTAFNTBPGGT1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | claimed |
| US-20030191119-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2003-10-09 | — | — | US | claimed |
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-09-26 | — | — | US | claimed |
| EP-0951464-A1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1998022430-A9 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | — | 1998-08-20 | — | — | WO | claimed |
| WO-1998022430-A1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6888022-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ATHENA NEUROSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6767918-B2 | ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-07-27 | — | — | US | disclosed |
| US-6642261-B2 | N-(phenylacetyl)alanine, isobutyl ester for example; prophylaxis and treatment of Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030191119-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2003-10-09 | — | — | US | disclosed |
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6333351-B1 | ENZYME INHIBITORS WITH CARRIERS | ATHENA NEUROSCIENCES, INC. | 2001-12-25 | — | — | US | disclosed |
| US-6313152-B1 | ADMINISTERING N(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS FOR THERAPY OF ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6117901-A | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use | ATHENA NEUROSCIENCES, INC. (US) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | POLB 2981/4885PSMB8 1017/4885PSMB5 967/4885 |
| US-20020137743-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, BACE1, IAPP | POLB 3668/4885PSMB8 938/4885PSMB5 502/4885 |
| US-20030191119-A1 | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, BACE1, IAPP | POLB 3668/4885PSMB8 938/4885PSMB5 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.